Delving into the Latest Updates on Menotropins with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Gonadoryl, Highly Purified Menotrophin, HMG

+ [12]

Target

FSHR x LHCGR

Action

agonists, stimulants

Mechanism

FSHR agonists(Follicle-stimulating hormone receptor agonists), LHCGR agonists(Luteinizing hormone/Choriogonadotropin receptor agonists), Ovarian follicle stimulants

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

Primary Ovarian InsufficiencyFemale infertility associated with anovulationPolyendocrine Metabolic Ovarian Syndrome+ [3]

Inactive Indication

Infertility, Male

Originator Organization

FERRING BV

Active Organization

Ferring Pharmaceuticals Pty Ltd.

Huiling Pharmaceutical Consulting (Shanghai) Co., Ltd.Ferring Pharmaceuticals, Inc.

Inactive Organization

Ferring Pharmaceuticals A/S

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (27 Aug 1999),

Infertility, Female

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 3246α

Sequence Code 3253β

Sequence Code 83626β

Ovarian stimulation (OS) is a key component of IVF, aimed at increasing oocyte yield and improving embryo development potential. While early protocols relied solely on FSH, newer approaches incorporate hMG and LH-based stimulation, allowing more individualized treatments for specific patient populations. Evidence suggests that hMG and recombinant FSH (rFSH) have comparable effectiveness in stimulation outcomes, and current guidelines support the use of both. However, the impact of different gonadotropins on embryo quality remains unclear, with mixed findings across protocols. Given the increasing use of combined rFSH and hMG and the limited data in PPOS protocols, this study proposes a randomized controlled trial to compare embryo quality between two different rFSH-hMG dosing strategies.

Start Date01 Sep 2026

Sponsor / Collaborator

Ferring Pharmaceuticals SA

NCT07568574

/ Enrolling by invitationNot Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting

Objectives:
The primary objective is to assess the safety and tolerability of medical drugs with the potential to enhance performance (PES) in professional athletes over a 5.5 year period, encompassing a 25-week PES Exposure period and 5 year long term follow-up of period comprehensive health and safety monitoring. The secondary objective is to evaluate the impact of PES on athletic performance through validated sport specific and clinical assessments.
Methods:
This prospective hybrid design study will enrol 60 adult participants, divided into two groups. The first group will receive performance-enhancing substances (PES) directly through the study, administered as Investigational Medicinal Products (IMPs) under comprehensive medical supervision for up to 25 weeks. The second group will include natural athletes and those already using PES prescribed by their own doctors. All substances used in this study are medically approved by national regulatory agencies (e.g., FDA, MHRA, EMA, EDE, etc.), and market authorised.
Participants undergo enrollment and baseline health and performance assessments, prior to a 25 weeks of PES exposure. During the period of PES exposure, participants undergo periodic monitoring of comprehensive physiological biomarkers alongside subjective assessments. Following the PES exposure phase, participants will complete repeat baseline health and performance assessments, followed by a titration phase and, where indicated, post-cycle therapy (PCT) to support the restoration of physiological function toward baseline. The study will conclude with a five-year longitudinal follow-up period to monitor long-term health outcomes. During this phase, participants will undergo annual assessments, including cardiac electrocardiography (ECG), echocardiography, magnetic resonance imaging (MRI), blood and urine biomarkers, routine vital signs, and quality-of-life measures. Additional imaging will include brain functional MRI (fMRI) and vital organ ultrasound at years 1, 3, and 5, with cardiac CT performed as clinically indicated. Athlete safety biomarker assessments, clinical evaluations, and adverse event reporting, will be continuously evaluated by study doctors and with additional safety oversight from a Data Safety Monitoring Board, Independent Medical Commission (a multidisciplinary panel of medical experts), and a Medical Monitor.

Start Date12 Mar 2026

Sponsor / Collaborator-

ChiCTR2500113652

/ SuspendedNot ApplicableIIT

Comparison of Clinical Outcomes between the GnRH Agonist Protocol and the Intensified Oestrogen Administration Protocol in Frozen Embryo Transfer Cycles for Patients with Thin Endometrium: A Prospective Randomized Controlled Study

Start Date01 Dec 2025

Sponsor / Collaborator

The First Affiliated Hospital of Wenzhou Medical College

100 Clinical Results associated with Menotropins

Login to view more data

100 Translational Medicine associated with Menotropins

Login to view more data

100 Patents (Medical) associated with Menotropins

Login to view more data

2,254

Literatures (Medical) associated with Menotropins

01 Aug 2026·Ophthalmology science

Deep Learning and Radiomics Assessment for Highly Myopic Glaucoma Detection Based on Fundus Photography

Article

Author: Wang, Yizhou ; Li, Zhidong ; Zhu, Yingting ; Zuo, Chenguo ; Chen, Xiaohong ; Zhuo, Yehong ; Zhao, Xiujuan ; Chen, Xuhao ; Hu, Lingjing ; Han, Wenjing ; Huang, Shaofen ; Luo, Man ; Zhou, Chen ; Lu, Lin ; Xiao, Hui

Purpose:

To investigate spatially distinctive features in fundus photographs of highly myopic glaucoma (HMG) by integrating radiomics and deep learning.

Design:

Cross-sectional study.

Participants:

Semi-automated optic disc segmentation was performed on 2000 images sourced from the Retinal Fundus Glaucoma Challenge Edition and Pathologic Myopia Challenge public data sets. We trained models with 628 images, including 217 cases of high myopia (HM), 221 cases of primary open-angle glaucoma (POAG), and 190 cases of HMG. An external validation set of 106 images was collected including 31, 36, and 39 fundus photographs from patients with HM, HMG, and POAG, respectively.

Methods:

Semi-automated optic disc segmentation was performed by U-Net combined with manual delineation. Additionally, 5 regions of interest (ROIs) covering the optic disc and its surrounding region were explored. Fundus photography-based radiomics feature selection and optimization were conducted using random forest and support vector machine algorithms, which underwent fivefold cross-validation. Model performance was evaluated for radiomics, clinical, and combined models. An external validation set was used to evaluate the models performance, and we also examined radiomics features varied across glaucoma stages.

Main Outcome Measures:

A total of 414 radiomics features were extracted from 5 regions of interest. We evaluated the model performance using accuracy, recall, precision, F1 score, and area under the receiver operating characteristic curve (AUROC). The Youden index was used to determine the cut-off value, and sensitivity and specificity were calculated.

Results:

The U-Net-based optic disc segmentation reached a Dice Similarity Coefficient of 0.95. The radiomics model detected HMG from HM and POAG achieved the accuracies of 0.97 and 0.85, respectively. Both results exceeded the performance of the clinical model, which achieved 0.90 and 0.71. The top radiomics features achieved AUROC of 0.984 and 0.855 for HMG versus HM and HMG versus POAG in the external validation, respectively, including intensity features in the extra-optic nerve and textural features in the optic nerve. These features showed strong diagnostic capability when stratified by Youden values and exhibited independence from glaucoma progression.

Conclusions:

The study combined U-Net and radiomics to delineate the spatial distribution biomarkers of HMG, establishing a quantitative classification model correlated with anatomical features.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

01 Aug 2026·REPRODUCTIVE BIOMEDICINE ONLINE

A plan for universal access to fertility care

Review

Author: Sable, David

In the 66 years since the introduction of clomiphene citrate, the 64 years since the first pregnancy using menotrophin stimulation and the 48 years since the birth of the first baby conceived through IVF, the procedures that have been developed to help millions of families to overcome infertility have become increasingly safe and effective. Our ability to provide access to the much larger population of underserved and unserved has, however, lagged far behind. As declining fertility rates bring renewed attention to access to fertility care, the challenge for reproductive medicine is to leverage the progress made in developing safe and effective treatment and make it universally available to those patients in need. This requires a strategy to address both cost of care and treatment capacity constraints, challenges made less daunting due to recent innovation and technology.

01 Jul 2026·BREAST CANCER RESEARCH AND TREATMENT

Assisted Reproductive Technologies (ART) and breast cancer risk: hormonal treatments under the spotlight

Review

Author: Lia, Francesca L ; Boldrini, Cristiana ; Bottalico, Micol ; Longo, Valentina ; Gigli, Silvia

Abstract:

Background:

Assisted Reproductive Technologies (ART) have become nowadays a cornerstone in the management of infertility. While these treatments are generally considered safe, concerns have been raised regarding their potential influence on breast cancer (BC) risk, particularly in specific subgroups of women.

Objective:

This narrative review aims to evaluate the most relevant past and current literature on the association between ART-related hormonal treatments and breast cancer risk, highlighting potential biological mechanisms, epidemiological evidence, and clinical implications.

Methods:

A literature search was conducted through PubMed, focusing on medium-to-large cohort and case-control studies, meta-analyses, and guidelines published to date. Evidence was synthesized by distinguishing overall ART/IVF risk estimates from drug-specific findings and subgroup-specific risk modifiers. Particular attention was given to the most recent or most comprehensive reports when multiple publications were derived from the same cohort.

Results:

To date, current evidence does not support a real and consistent overall increase in breast cancer risk following ART-related hormonal treatments. Large population-based studies and recent meta-analyses are generally reassuring, particularly when ART-treated women are compared with infertile untreated women rather than with the general population. Some studies report modest risk elevations in selected subgroups, including nulliparous or nulligravid women, women undergoing repeated or high-dose stimulation cycles, and women with hereditary BC predisposition; however, these findings are inconsistent and often limited by residual confounding, small subgroup numbers, and incomplete dose information. Progesterone supplementation appears safe in the context of ART, with no consistent evidence of increased BC risk. Gonadotropins, including hMG, may transiently increase estrogen exposure, but large-scale studies and meta-analyses generally do not confirm a long-term increase in breast cancer incidence.

8

News (Medical) associated with Menotropins

10 Mar 2026

·www.biospace.com

For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025

Ferring's total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur ® Continued ramp-up in the US for Adstiladrin ® , our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driver Commitment to sustainability demonstrated by SBTi approval of our targets to reduce greenhouse gas emissions, and by our programme to reduce maternal deaths in low- and lower middle-income countries SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring today published its 2025 Annual Report and Sustainability Report . The company achieved total revenues of over €2.5 billion in 2025, an increase of 7% over the previous year at actual exchange rates (AER) and 10% at constant exchange rates (CER). These were mainly driven by our flagship product Menopur ® (menotropins for injection) in reproductive medicine, and the ramp-up in the US of our breakthrough gene-based therapy for non-muscle invasive bladder cancer, Adstiladrin ® (nadofaragene firadenovec-vncg). Operating expenses were contained to an increase of €61 million year-on-year (i.e. +5% at AER and +7% at CER), and this includes significant non-recurring items (notably impairment charges and restructuring provisions). Underlying operating expenses remained well-controlled, with increased investments targeted to support the growth of Adstiladrin and other opportunities. Thus, operating profit for the year reached €167 million, a decrease of -€24 million (‑13%) versus the prior year at AER, while remaining flat at CER - with the difference being driven by the weaker US dollar. Following a focus on improving cash conversion after several heavy investments, free cash flow generation approached neutral despite currency headwinds from the weaker US dollar. This represents a substantial improvement compared to the previous year, and a significant step towards sustainable cash generation. Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer, said: “This was a pivotal year as we continued evolving our business to become stronger, more agile and more resilient, and importantly we got back to free cash flow neutral. Moreover, in 2025, we introduced an enterprise model designed to create greater value for patients and customers while supporting sustainable growth. This reflects our long-term commitment to serving patients’ need, and fostering an environment where people can learn, grow and perform at their best.” Ferring has always conducted business responsibly by seeking to protect the environment, create value for society, and uphold our high standards of ethics and governance. In 2025, we passed a major milestone when our targets for reducing greenhouse gas (GHG) emissions were approved by the Science Based Targets initiative (SBTi). This globally recognised standard ensures corporate goals are aligned with international climate policy. During the year, we succeeded in reducing our Scope 1 and 2 GHG emissions by 4.3% and Scope 3 emissions by 19%. Access to affordable healthcare is embedded in Ferring’s purpose and strategic priorities. The Project Family™: Safe Birth initiative aims to reduce maternal deaths in low- and lower middle-income countries by enabling wider access to Carbetocin Ferring (carbetocin, room-temperature stable formulation). In 2025, we worked with partners to supply around 1.7 million doses of this life-saving medicine at an affordable access price, while gaining further approvals in seven low- and lower middle-income countries. About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. Learn more at , or connect with us on LinkedIn , Instagram and YouTube . Contacts For more information, please contact Carine Julen Senior Manager, Corporate Communications & Public Affairs carine.julen@ferring.com

Gene TherapyDrug ApprovalFinancial Statement

21 Jul 2025

·www.fiercepharma.com

Ferring summons star power to celebrate World IVF Day with firsthand fertility stories

All three of Ferring’s new celebrity partners have firsthand experience with using in vitro fertilization to grow their families, and all expressed the importance of community throughout the process. Real Housewives and Olympians and social media-famous physicians, oh my! Ferring Pharmaceuticals has assembled a roster of familiar faces to boost its community-building efforts around fertility, tied to this week’s World IVF Day.World IVF Day is celebrated every year on July 25 in honor of the day the first baby was born via in vitro fertilization in 1978. The awareness day “reminds us how far fertility care has come and how much further we need to go,” David Powley, Ferring’s vice president of reproductive medicine, said in a Monday announcement.Ahead of this year’s commemoration, Ferring has recruited “Real Housewives of New York City” star Jessel Taank, gold-medal-winning figure skater Tara Lipinski and well-known reproductive endocrinologist Lucky Sekhon, M.D., to continue the company’s work to normalize discussions about infertility by sharing their own experiences with IVF.The starry group will help spotlight Ferring’s “Fertility Out Loud” platform. The site launched in 2021 to offer information about infertility and treatment options, provide helpful resources and share real stories from people at various points on their fertility journeys.All three of Ferring’s new celebrity partners have firsthand experience with using IVF to grow their families, and all expressed in statements the importance of community throughout the process. As Lipinski said, “What helped me most was connecting with others and leaning on trusted resources for comfort and guidance. That kind of perspective, reassurance and encouragement is exactly what Fertility Out Loud provides. While becoming a parent is deeply personal, by sharing our stories, we can help uplift each other.” Ferring is the maker of several fertility-related products, including Menopur and Novarel, used to induce ovulation in women experiencing infertility, and Endometrin, which provides extra progesterone to women undergoing fertility treatments.In the years since launching the unbranded Fertility Out Loud platform, the company has continued to add new resources to the site, like the 2022 introduction of text-message-based access to live fertility coaches and 2023’s debut of a docuseries tracking four couples’ diverse paths to parenthood.Most recently, last summer, Ferring partnered with virtual male fertility clinic Posterity Health to roll out educational information and a confidential digital assessment to help men better understand their own fertility issues and fight stigma in that realm.

20 Jun 2024

·www.fiercepharma.com

Ferring launches online assessment tool, educational platform around male fertility

The overall goal of the initiative is to make the entire fertility journey more equitable for both women and men, which, according to Ferring, may ultimately help “improve drop-out rates, decrease stress, address stigma, reduce unnecessary medical costs and accelerate the path to pregnancy.” Ferring Pharmaceuticals is setting the record straight on fertility issues. Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility. The issue is further compounded by stigma that may make men feel emasculated or embarrassed to be struggling with their fertility. A new initiative from Ferring, however, is aiming to boost awareness and education around male fertility and break down that stigma. According to a company announcement Thursday, the program was launched in partnership with Posterity Health, a virtual care service focused on male reproductive health and is hosted on Ferring’s existing Fertility Out Loud platform, which launched in 2021 to provide support for aspiring parents. The platform’s new addition will specifically target men, to “activate them to learn about their fertility health and how it may impact the couple’s path to parenthood,” according to Ali Castro, senior director of marketing and strategic engagement for Ferring’s reproductive medicine division. To do so, it’ll offer both educational resources and a confidential digital assessment that male partners can use to gain a better idea of their personal reproductive health. The overall goal of the initiative is to make the entire fertility journey more equitable for both women and men, which, according to Ferring, may ultimately help “improve drop-out rates, decrease stress, address stigma, reduce unnecessary medical costs and accelerate the path to pregnancy.” “When a couple is having trouble conceiving, the male partner typically waits 22 months before seeking an evaluation—during this period the female is often receiving unnecessary, and in some cases, invasive care,” Pam Pure, co-founder and CEO of Posterity, said in the announcement. “Working together with Ferring, we have made it easier to complete a male fertility assessment from home. Identifying and addressing male factor issues early in the fertility journey will empower couples to take control of their reproductive health.” Both the new initiative and larger Fertility Out Loud platform are unbranded, hosted on a standalone site with the only mention of Ferring at the bottom of each page. That said, Ferring does offer several fertility-related products, including Menopur and Novarel, both of which are used to induce ovulation in women struggling with infertility, and Endometrin, which provides extra progesterone to women who are undergoing fertility treatments.

100 Deals associated with Menotropins

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02692	Menotropins	G03GA02	DB00032

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Primary Ovarian Insufficiency	United States	Ferring Pharmaceuticals, Inc.	19 Feb 2014
Female infertility associated with anovulation	Australia	Ferring Pharmaceuticals Pty Ltd.	13 Sep 2011
Polyendocrine Metabolic Ovarian Syndrome	Australia	Ferring Pharmaceuticals Pty Ltd.	13 Sep 2011
Anovulation	United States	Ferring Pharmaceuticals, Inc.	29 Oct 2004
Infertility	United States	Ferring Pharmaceuticals, Inc.	29 Oct 2004
Infertility, Female	United States	Ferring Pharmaceuticals, Inc.	27 Aug 1999

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infertility, Male	Phase 3	Belgium	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility, Male	Phase 3	Czechia	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility, Male	Phase 3	Denmark	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility, Male	Phase 3	Poland	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility, Male	Phase 3	Spain	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility, Male	Phase 3	Sweden	Ferring Pharmaceuticals A/S	01 Jul 2009
Infertility, Male	Phase 3	Turkey	Ferring Pharmaceuticals A/S	01 Jul 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05103228 (CTgov)	Not Applicable	Infertility \| Diminished ovarian reserve \| Ovarian Diseases	190	human menopausal gonadotropin+Follitropin delta+Follitropin Alfa (Lower Gonadotropin Dose Stimulation)	dikebhnvzk = tkwejiznpr efrmhlpamd (btzukzhldd, cmlnfcrnny - obptiazkwf) View more	-	13 Dec 2024
				human menopausal gonadotropin+Follitropin delta+Follitropin Alfa (Higher Gonadotropin Dose Stimulation)	dikebhnvzk = ugodeexqja efrmhlpamd (btzukzhldd, hfjyqzxzxz - ubwsxvlcvv) View more
NCT04163458 (CLARA, CTgov)	Phase 3	Infertility \| Infertility, Male	405	Placebo (for MENOPUR powder and solvent for solution for injection)+MENOPUR (MENOPUR Liquid)	cexjuuxbts(bfdevcumdj) = miwppivjvr peavriggex (rwbtkrvqur, 5.5) View more	-	07 Nov 2023
				Placebo (for MENOPUR solution for injection in pre-filled pen)+MENOPUR powder and solvent for solution for injection, 75 IU (MENOPUR Powder)	cexjuuxbts(bfdevcumdj) = cwyjrfoczc peavriggex (rwbtkrvqur, 4.2) View more
NCT02554279 (MEGASET-HR, Pubmed)	Phase 4	-	620	Highly purified human menotropin (HP-hMG)	fvsvqmqbum(jjinuojvps) = yjtfimlluk nnhtsxhdju (rmadkoqwth )	-	01 Dec 2020
				Recombinant follicle-stimulating hormone (FSH)	fvsvqmqbum(jjinuojvps) = fdoahygnsm nnhtsxhdju (rmadkoqwth )
NCT02554279 (MEGASET HR, Pubmed \| Fertil Steril) Manual	Phase 4	Ovarian Stimulations	619	highly purified human menotropin	kujtxsynwz(vqhuvcnmel) = faolkxktxr bwtosaihic (bafdvrshtl ) View more	Negative	01 Aug 2020
				recombinant follicle-stimulating hormone	kujtxsynwz(vqhuvcnmel) = kjourerghk bwtosaihic (bafdvrshtl ) View more
NCT02554279 (MEGASET-HR \| MEGASET HR, CTgov)	Phase 4	Infertility	620	menotropin (Menotropin)	oibzqavtvp = nthkeeumep ahqvxleses (fbmlwatqzp, ciabqbixew - xddvewgrka) View more	-	02 Mar 2018
				recombinant FSH (Recombinant FSH)	oibzqavtvp = tdioeskcbo ahqvxleses (fbmlwatqzp, vdvycyuyij - bmpcowvxjx) View more
NCT01921166 (Diminished Ovarian Reserve, CTgov)	Phase 4	Infertility	23	Menopur+Clomid+Bravelle+Follistim+Gonal f (Clomiphene Plus Gonadotropins)	rugbznnggc = unuyivdpwa muddzczdbn (mzoglojiei, izpuvumoxq - vhjjdkcfbv) View more	-	23 Feb 2018
				Leuprolide flare (Leuprolide Flare)	rugbznnggc = tmkmkclibi muddzczdbn (mzoglojiei, vbpqcszxvq - olapccupka) View more
NCT02542280 (CTgov)	Phase 3	Infertility \| Endometritis	360	endometrial injury. (Endometrial Injury)	ooieinaytx = qmpzlsdlji dteyebfces (ravwdwjygc, sznpnjkywl - ixkrwrpxhs) View more	-	08 Jan 2016
				ovarian stimulation (no Endometrial Injury)	ooieinaytx = ckpxwtfbzi dteyebfces (ravwdwjygc, zpcrfwgaur - acgkrbjkcn) View more
NCT01569945 (Pubmed \| Hum Reprod)	Not Applicable	Infertility	657	Low-dose human menopausal gonadotrophin	gtppnvewhx(bsnwcqyjdt) = fehcrmmedc vjanrewqgm (xyecnqmcbm ) View more	-	01 May 2015
				Clomiphene citrate	gtppnvewhx(bsnwcqyjdt) = ggugzalaqd vjanrewqgm (xyecnqmcbm ) View more
NCT01312766 (CTgov)	Phase 3	Infertility	270	Menotropins (hMG-IBSA)	cofkrgxvnm(ediqjmzlgy) = rcsdaqjjau vyaiesbnih (syerlutwgb, 6.6) View more	-	15 Aug 2014
				Menotropins (Menopur)	cofkrgxvnm(ediqjmzlgy) = mddypwdjba vyaiesbnih (syerlutwgb, 5.9) View more
NCT01417195 (COMBINE, CTgov)	Phase 4	Infertility	122	Bravelle+Menopur (Menopur and Bravelle Combination)	fbcbmddjox(ctskeupitg) = yfchaukfmj ebzyresivt (fheczufarh, 21.567) View more	-	24 Apr 2014
				Menopur (Menopur Alone)	fbcbmddjox(ctskeupitg) = tqkvkajwue ebzyresivt (fheczufarh, 22.460) View more